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Background: Duchenne muscular dystrophy (DMD) is one of the most frequent forms of muscular disorders. It is
caused by the absence of dystrophin, a core component of the sarcolemma-associated junctional complex that
links the cytoskeleton to the extracellular matrix. We showed previously that plectin 1f (P1f), one of the major
muscle-expressed isoforms of the cytoskeletal linker protein plectin, accumulates at the sarcolemma of DMD
patients as well as of mdx mice, a widely studied animal model for DMD.
Based on plectin’s dual role as structural protein and scaffolding platform for signaling molecules, we speculated
that the dystrophic phenotype observed after loss of dystrophin was caused, at least to some extent, by excess
plectin. Thus, we hypothesized that elimination of plectin expression in mdx skeletal muscle, while probably
resulting in an overall more severe phenotype, may lead to a partial phenotype rescue. In particular, we wanted to
assess whether excess sarcolemmal plectin contributes to the dysregulation of sugar metabolism in mdx myofibers.
Methods: We generated plectin/dystrophin double deficient (dKO) mice by breeding mdx with conditional striated
muscle-restricted plectin knockout (cKO) mice. The phenotype of these mice was comparatively analyzed with that
of mdx, cKO, and wild-type mice, focusing on structural integrity and dysregulation of glucose metabolism.
Results: We show that the accumulation of plectin at the sarcolemma of mdx muscle fibers hardly compensated for
their loss of structural integrity. Instead, it led to an additional metabolic deficit by impairing glucose uptake. While dKO
mice suffered from an overall more severe form of muscular dystrophy compared to mdx or plectin-deficient mice,
sarcolemmal integrity as well as glucose uptake of their myofibers were restored to normal levels upon ablation of
plectin. Furthermore, microtubule (MT) networks in intact dKO myofibers, including subsarcolemmal areas, were found
to be more robust than those in mdx mice. Finally, myotubes differentiated from P1f-overexpressing myoblasts showed
an impairment of glucose transporter 4 translocation and a destabilization of MT networks.
Conclusions: Based on these results we propose that sarcolemma-associated plectin acts as an antagonist of MT
network formation in myofibers, thereby hindering vesicle-mediated (MT-dependent) transport of glucose transporter 4.
This novel role of plectin throws a bridge between extra-sarcomeric cytoarchitecture and metabolism of muscle fibers.
Our study thus provides new insights into pathomechanisms of plectinopathies and muscular dystrophies in general.
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Plectin is an important cytolinker protein that is responsible
for the networking and anchorage of intermediate filaments
(IFs) to organelles and junctional complexes. It is expressed
as multiple isoforms with different short N-terminal se-
quences (generated by alternative 5′-splicing) that deter-
mine their differential cellular targeting [1,2]. Being bound
to different cellular structures via their N-termini and
recruiting IFs via their C-termini, plectin isoforms play piv-
otal roles in shaping the cytoarchitecture of cells, with con-
sequences for vital cellular features such as polarity and
migratory potential [3,4]. Dysfunction or absence of plectin
leads to epidermolysis bullosa simplex (EBS), a skin blister-
ing disease that in most cases is associated with muscular
dystrophy [5,6]. In myofibers, the contractile apparatus is
suspended in a network of desmin filaments linked to the
nuclear envelope and the sarcoplasmatic reticulum via
plectin isoform 1 (P1), to sarcolemmal costameres and Z-
disks via P1f and P1d, respectively, and to mitochondria
via P1b [7-9]. Apart from functioning as structural
reinforcement and organizing elements of the cytoskel-
eton, plectin isoforms play also an important role as scaf-
folding platforms for signaling proteins involved in cell
metabolism, stress response, and motility [10-13].
Isoform P1f was found to be overexpressed at the sarco-
lemma of patients suffering from various types of muscu-
lar dystrophy as well as in regenerated muscle fibers
of mdx mice, a mouse model for DMD [7,14]. X-
chromosome-linked DMD is the most frequent form of
muscular dystrophy with an incidence rate of 1 in 3,500
live male births [15]. It is characterized by the absence of
full-length dystrophin, an approximately 400 kDa protein
that is important for maintaining muscle fiber architecture
[16]. Overexpression of plectin at the sarcolemma of
DMD and mdx myofibers in response to the loss of dys-
trophin could be a compensatory mechanism for stabiliz-
ing costameres and the plasma membrane-associated
protein skeleton. In fact, plectin was found to interact with
the same binding domain of β-dystroglycan that normally
is occupied by dystrophin [7].
Generally, mdxmice show a milder form of muscular dys-
trophy than DMD patients and in comparison live longer
(for review see [17]). A larger muscle stem cell pool owing
to the longer telomers of mouse chromosomes [18] and/or
impaired differentiation of muscle fiber precursor (satellite)
cells [19] has been suggested as being responsible for these
differences. Mdx mice were also reported to have an in-
creased body weight [20], in line with the impaired metabol-
ism described for mdx-derived skeletal muscles [21] and
dystrophin-deficient myoblasts [22]. Thus, the mdx mouse
system has the potential to serve as a genetically manipu-
lable tool not only for studying plectin’s role as structural
reinforcement element of the sarcolemma but also for inves-
tigating plectin-dependent metabolic processes.Thus, we hypothesized that the elimination of plectin ex-
pression in mdx skeletal muscle, while probably resulting
in an overall more severe phenotype, may lead to a partial
phenotype rescue. Especially, an interference of excess P1f
with signaling and/or regulatory processes involved in
glucose metabolism seemed conceivable. Glucose metabol-
ism involves the translocation of glucose transporter 4
(GLUT4) from the cytoplasm to the sarcolemma as a result
of insulin dependent or independent signaling pathways
(for review see [23]). This translocation requires an intact
cell membrane and cortical actin system to allow fusion of
GLUT4-loaded vesicles with the sarcolemma, as well as a
properly functioning microtubule (MT) network for long-
distance vesicle transport (for review see [24]).
To test our hypothesis we investigated whether plectin
indeed plays a role in glucose metabolism. For this, we
crossed mdx mice with striated muscle-restricted condi-
tional plectin knockout mice, thus generating a mouse line
that in addition to dystrophin was lacking plectin in
myofibers. We show that the ablation of plectin, while dras-
tically reducing the lifespan and worsening the overall
phenotype of mdx mice, led to a reversion of impaired glu-
cose uptake and partial restoration of sarcolemmal integrity
in their muscle fibers. On the mechanistic level, we show
that sarcolemma-associated plectin acts as a destabilizer of
MTs and thereby affects the translocation of GLUT4.
Methods
cDNA constructs
Full-length mouse P1f-EGFP (pGR258) has been de-
scribed previously [2]. pmCherry-HA-GLUT4 is an ex-
pression plasmid that encodes mCherry-tagged human
GLUT4 containing a hemagglutinin (HA) tag within an
exofacial loop, generated by inserting a BamHI/HindIII
fragment from GFP-HA-GLUT4 (a kind gift of Samuel
W Cushman, NIDDK, Bethesda, MD, USA [25]) into the
corresponding sites of a modified pmCherry-C1 (a kind
gift of Anna Akhmanova, Erasmus MC, Rotterdam,
Netherlands, who originally received mCherry cDNA
from R Y Tsien, University of California, San Diego, CA,
USA); a shift of the open reading frame by two bases
was introduced by BglII-digestion, incubation with mung
bean nuclease, and subsequent religation. mCherry-HA
was generated by inserting an oligonucleotide (HA fw:
5′-GAT CTT ACC CAT ACG ATG TTC CAG ATT
ACG CTT GAG GTA C-3′; HA rev: 5′-CTC AAG
CGT AAT CTG GAA CAT CGT ATG GGT AA-5′) en-
coding the HA-tag after annealing and restriction with
BglII/KpnI into the corresponding sites of pmCherry-C1.
Mice and cell lines
Experiments involving mice were approved by the
Austrian Federal Government. Conditional striated muscle-
restricted plectin knockout (cKO) mice lacking all isoforms
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with muscle creatine kinase (MCK)-Cre mice (provided by
C R Kahn, Joslin Diabetes Center and Harvard Medical
School, Boston, MA, USA) as previously described [8]; for
mdx mice see [26]. dKO mice were generated by breeding
cKO with mdx mice. Unless otherwise stated, eight to ten-
week-old male littermates were used for experiments. Pri-
mary myoblasts were isolated from two to three-day-old
wt,mdx, cKO, or dKO newborns following established pro-
tocols [27]. After two to three passages, cells were differen-
tiated to myofibers for seven days. For some experiments
(double transfection with P1f/GLUT4, and counting of
MTs) an immortalized mouse myoblast cell line was
used [11].
Antibodies
For immunofluorescence microscopy (IFM) and im-
munoblotting (IB) the following antibodies were used:
mAb to α-tubulin (IFM; Acris, Herford, Germany), mAb
to desmin (IFM; Dako Cytomation, Glostrup, Denmark),
antisera #9 (IB) and #46 (IFM) to plectin [28], anti-
GLUT4 (IFM; a kind gift from Dr. Hadi Al-Hasani,
German Diabetes Center, Düsseldorf, Germany; IB; #2299;
Cell Signaling, Danvers, MA, USA), anti-sarcomeric α-
actinin (IFM; Sigma, St. Louis, MO, USA), anti-dystrophin
(IB; NCL-Dys1; Leica Biosystems Newcastle Ltd, Newcastle
upon Tyne, UK), anti-α-tubulin (IB; DM1A, Abcam,
Cambridge, UK), anti-acetylated tubulin (IB; 6-11-B1;
Sigma, St. Louis, MO, USA), anti-tau (IB; A0028; Dako,
Glostrup, Denmark), and mAB to HA-tag (GLUT4
translocation assay; HA.11; Covance, Berkeley, CA,
USA). As secondary antibodies we used donkey anti-rat
633, goat anti-rat Cy5, goat anti-mouse 488, and donkey
anti-mouse Dylight 649 for IFM and HRPO-conjugated
goat anti-rabbit or goat anti-mouse for IB (all Jackson
ImmunoResearch, West Grove, PA, USA).
Histology
Histological analyses were performed using cryosections
following standard protocols. Fiber types were assigned
based on ATPase (pH 4.2) staining. To measure fiber di-
ameters, individual fibers were manually circumscribed
with polygons and, in order to compensate for skewed
sections, a custom computer program then calculated
diameters as the maximal length inside each polygon or-
thogonal to the largest diameter of the polygon.
Immunohistochemistry
Teased muscle fibers were prepared in MT-stabilizing buf-
fer from EDL muscle as described previously [7] and MTs
were stained with antibodies to α-tubulin and 633-
conjugated secondary antibodies. Myofibers derived from
myoblasts co-transfected with pmCherry-HA-hGLUT4
and pGR258 (plectin 1f-EGFP) were immunolabeled usingmAbs to α-tubulin and goat anti-rat Cy5-conjugated sec-
ondary antibodies after fixing the cells in 4% PFA at room
temperature. To measure MT stability in primary myo-
blasts, cells were incubated with 1 μM nocodazole for 30
minutes at 37°C, washed, fixed for 30 minutes with 2.5%
PFA, and stained with mAbs to α-tubulin/Cy5 and mAbs
to desmin/488. The total length of MTs was then mea-
sured in randomly chosen microscopic fields using
LSM510 software (Zeiss, Oberkochen, Germany) in an
observer-blinded manner and divided by the area occupied
by cells. Nuclei were stained using Hoechst 33258 (Sigma,
St. Louis, MO, USA).
GLUT4-specific signals in peripheral (sarcolemmal) and
interior (cytoplasmic) subcompartments of cryosectioned
QF muscle fibers were quantified by manually inscribing
and circumscribing the sarcolemmal regions of individual
fibers with polygons and measuring the fluorescence in-
tensity per unit area in the two resulting compartments
using ImageJ software (NIH Image, Bethesda, MD, USA).
Immunoblotting
Protein expression levels were determined densitomet-
rically after separation of proteins contained in GC
muscle lysates by SDS-PAGE, subsequent transfer to
nitrocellulose and immunodetection using antisera to
plectin, dystrophin, GLUT4, α-tubulin, acetylated tubu-
lin, or tau; and HRPO-conjugated goat anti-rabbit or
goat anti-mouse secondary antibodies. Quantification
of bands was performed using Quantiscan (Biosoft,
Cambridge, UK). Expression levels were normalized to
total protein content which was determined from corre-
sponding Coomassie-stained gels by measuring the in-
tensities of four different bands per lane that showed the
same relative intra-lane intensities.
Oral glucose tolerance test (oGTT) and insulin
measurement
oGTT was performed after fasting mice overnight. Mice
were force-fed by an oral gavage with glucose (2 g/kg body
weight) and blood samples were collected from the tail
vein at the indicated time points. Blood glucose and insu-
lin levels were determined with a standard glucometer
(OneTouch Ultra 2, Lifescan, Milpitas, CA, USA) and a
low sample volume insulin ELISA (Mercodia, Uppsala,
Sweden), respectively.
Differential blood count and CK measurements
Blood smears were stained with May-Gruenwald-Giemsa
solution and one hundred white blood cells were
counted per slide. CK activity in the plasma was deter-
mined using CK-NAC FS reagent (DiaSys, Holzheim,
Germany) according to the manufacturer’s instructions.
Additionally, CK activity was analyzed in diluted total
muscle lysates of GC muscle using a similar protocol.
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PCR on cDNA samples transcribed from 1 μg total RNA
prepared from QF muscle using as primers: 5′-CCT
GTT TGA TCC CAT CAT CC-3′ (fw) and 5′-AGC
ACA TAG TTG GGG TCC AG-3′ (rev). For normali-
zation, primers for HPRT1 (fw: 5′-CAG GCC AGA
CTT TGT TGG AT-3′; rev: 5′-TTG CGC TCA TCT
TAG GCT TT-3′) were used.
EBD penetration assay
Mice were injected intraperitoneally with 10 μls/g body
weight of a sterile 1% EBD solution in PBS, and after 24
hours sacrificed by cervical dislocation. Dissected exten-
sor digitorum longus (EDL) muscles were immediately
transferred to isopentane pre-cooled in liquid nitrogen.
Five-μm-cross-sections were prepared using a cryotome
(Zeiss HM 500 OM, Zeiss, Oberkochen, Germany) and
stored at −80°C until use. To check for EBD-positive
fibers, cryosections were fixed for one minute with
acetone, mounted in Histofluid, and subjected to im-
munofluorescence analysis using a bandpass filter (575
to 640 nm). Whole cross-sectional areas of two
cryosections from three different animals per genotype
were scored for EBD positive fibers.
GLUT4 translocation assay
Mouse myoblasts were transfected with pmCherry-
HA-hGLUT4 and pGR258 (P1f-EGFP) or pmCherry-
HA using the Amaxa NHDF nucleofector kit (Lonza,
Cologne, Germany) according to the manufacturer’s
instructions (program U-023) and differentiated for
seven days. Differentiated myoblasts were washed
twice with PBS and incubated for 10 minutes in
Krebs Ringer bicarbonate solution (KRB). Cells were
then incubated in KRB containing 100 μU insulin (Eli
Lilly, Toronto, Canada) and 120 μg anti-HA-tag anti-
bodies for 20 minutes at 37°C. After two washing steps
with KRB, cells were incubated with secondary antibody
(Dylight 649) diluted (2.8 μg/ml) in KRB. Cells were fixed
for 90 seconds with ice-cold methanol, washed twice with
PBS and once with water, and mounted in Mowiol 4–88
(Hoechst, Frankfurt, Germany). Digital images were
obtained using a Zeiss LSM 510 confocal microscope (Carl
Zeiss, Oberkochen, Germany) and colocalization was mea-
sured in ImageJ (http://rsbweb.nih.gov/ij/) using Costes’
approach [29].
Statistical analyses
Kruskal-Wallis and Mann–Whitney U tests were used
for comparison of the four different genotypes tested.
Student’s t-test was used for evaluation of GLUT4 trans-
location, MT counting, and MT stability in primary
myofibers. Calculations were done in SPSS 16.0 (IBM,
Armonk, NY, USA).Results
Plectin deficiency aggravates the muscular dystrophy
phenotype of mdx mice
To assess plectin’s contribution to the phenotype
displayed by mdx mice, dystrophin/plectin double KO
mice (dKO) were bred by crossing mdx with striated
muscle-restricted conditional plectin knockout (cKO)
mice. To allow for optimal comparison of phenotypes, a
breeding scheme was employed that generated all four
genotypes of interest (wt, MCK-Cre/cKO, mdx, and
dKO) in the male offspring within single litters (plectin
and dystrophin immunoblots are shown in Additional
file 1: Figure S1). The lifespan of dKO mice (5 to 17
weeks) turned out to be considerably lower than that of
cKO or mdx mice, which showed increased mortality
rates only after 26 weeks (cKO; [8]), or an almost normal
lifespan of approximately 21 months (mdx; [30]; and
data not shown) (Figure 1A). As the MCK promoter
which drives the Cre-mediated knockout of plectin in
skeletal muscle is also active in heart, the shorter life
span of dKO mice could have been due to heart failure.
In fact, the desmin IF system was severely disturbed
in dKO mice, as revealed by immunostaining of
cryosectioned hearts (Figure 1B). However, the extent of
IF disorganization and aggregate formation was very
similar to that observed in the considerably longer-lived
cKO mice [8]. For this reason we considered it unlikely
that the lack of plectin in the hearts of dKO mice was
the primary cause of their death. More likely, the shorter
lifespan of dKO mice was due to their strong muscle
wasting which was paralleled by a reduction of their
body weight (peaking at around 10 weeks of age and
rapidly declining thereafter; Figure 1C). In contrast, mdx
mice showed an increased body weight, consistent with
a reduced metabolism.
Comparative histopathological analyses of soleus and
EDL muscles from 10-week-old dKO, cKO, mdx, and wt
mice revealed atrophic fibers, fibers with central nuclei,
and an increase in fibrotic tissue in dKO mice (Additional
file 2: Table S1 and Additional file 3: Figure S2). Further-
more, aggregates of mitochondria were more prominent
in dKO compared to cKO muscle [8] while no abnormal-
ities in the distribution of mitochondria were observed in
mdx muscle. Contrary to cKO and mdx fibers, the major-
ity of dKO fibers appeared to be under high oxidative
stress as indicated by strong signals for NADH. This was
particularly striking in the case of EDL, a muscle predom-
inantly consisting of glycolytic type II fibers which gener-
ally have a lower oxygen capacity (Additional file 3:
Figure S2).
Using the adenosine triphosphatase (ATPase) reaction
at pH 4.2 to analyze the fiber type composition of dKO
soleus muscle, a statistically significant shift from fast-
twitch glycolytic type II fibers to slow aerobic (oxidative)
Figure 1 Phenotypic analyses of dKO mice compared to wt, cKO, and mdx mice. (A) Lifespan (n = 54 per genotype). (B)
Immunofluorescence microscopy of heart cryosections. Note aggregates of desmin (arrows) and plectin-positive connective tissue (asterisks) in
cKO and dKO samples. Bar, 10 μm. (C) Body weight. Note reduced weight of dKO mice compared to wt and cKO littermates, and increased
weight of mdx mice (n ≥ 55 per genotype). (D) Fiber type distribution in soleus muscle determined by ATPase staining (pH 4.2). Values represent
percent mean ± SEM of total fibers (n ≥ 3 per genotype; *P < 0.05). (E) Diameters of type I and II fibers. Median (line in box), 25th (bottom line of
box), 75th (top line of box), 5th and 95th (whiskers) percentiles are indicated (n ≥ 3 per genotype; **P < 0.01, ***P < 0.001).
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while in mdx muscles, compared to wt, a higher number
of hypertrophic fibers and increased heterogeneity in the
diameters of both type I and type II fibers were observed
(see also [31]), in dKO mice the diameters of both fiber
types were similar to those of wt littermates (Figure 1E).
This observation would be consistent with the idea that
plectin deficiency led to a rescue of the hypertrophy
phenotype typical of mdx mice. However, since it is
known that active muscle contraction is another import-
ant factor for skeletal muscle size and fiber type main-
tenance, the normal size of dKO myofibers could have
equally well been due to the visually observable de-
creased physical activity of dKO mice.The severe necrosis in dKO muscle was also reflected
in differential blood cell counts showing an increased
proportion of neutrophile granulocytes and a corre-
sponding reduction of lymphocytes (Additional file 4:
Figure S3). In summary, although the combined loss of
plectin and dystrophin, as predicted, led to an aggrava-
tion of the dystrophic muscular phenotype, a number of
abnormalities observed in mdx mice were fully or par-
tially rescued after deletion of plectin (see also below).
Plectin deficiency restores sarcolemmal integrity in mdx mice
Plasma levels of creatine kinase (CK), which serve as an
indicator for sarcolemma integrity [32], showed an ap-
proximately 30-fold increase in mdx over wt mice,
Raith et al. Skeletal Muscle 2013, 3:14 Page 6 of 14
http://www.skeletalmusclejournal.com/content/3/1/14whereas in dKO mice they were only approximately
eight-fold increased (equivalent to an approximately
four-fold lower CK levels in dKO compared to mdx
mice). cKO mice showed non-pathological levels of CK
(Figure 2A). When CK activities were measured in
muscle lysates, the situation was different, as in this case
all the mouse lines affected by muscular dystrophy, in-
cluding cKO mice, showed reduced activities without
any significant differences among them (Figure 2B). A
similar pattern was observed for CK mRNA expression
levels (Figure 2C). In an alternative test of sarcolemma
integrity, the barrier function of myofibers was assessed
after peritoneal injection of Evans Blue dye (EBD). While
in mdx mice EBD-positive myofibers were clearly detect-
able, in wt, cKO, and dKO mice no dye penetration was
observed (Figure 2D). These observations were consist-
ent with the markedly increased plasma CK levels of
mdx mice (Figure 2A).
Metabolic defects of mdx mice are absent from dKO mice
The increased body weight of mdx mice ([20]; and
Figure 1C) and the previously reported defects in meta-
bolic regulation observed in mdx skeletal muscle [21]
and dystrophin-deficient myoblasts [22], were consistent
with a deregulation of sugar uptake. To directly assessFigure 2 Measurements of sarcolemma integrity. (A and B) CK activitie
and in GC muscle tissue lysates (B) (n = 3 per genotype; *P < 0.05). (C) CK
to the levels of the reference gene HPRT1 and normalized to wt muscle (n
tissue was assessed by immunofluorescence microscopy of cryosections fro
of two cryosections per genotype were examined). Note EBD-positive fiberwhether plectin’s sarcolemmal accumulation in mdx
muscle fibers contributed to such deregulation, wt and
mutant mice were subjected to oral glucose tolerance
tests (oGTT). Interestingly, while confirming that the
uptake of blood sugar by mdx muscle was severely ham-
pered (Figure 3A), these tests revealed normal glucose
uptake in dKO as well as in cKO mice. Thus, plectin de-
ficiency seemed to restore the glucose uptake capacity of
mdx muscle, thereby rescuing its metabolic deficit. Mea-
surements of plasma insulin levels showed that all types
of mice responded normally to force-fed glucose
(Figure 3B), demonstrating that insulin secretion was
not affected. To investigate whether insulin-independent
metabolic mechanisms had any effect on glucose uptake,
we determined expression levels of the active (subunit
alpha-phosphorylated) form of AMP-activated kinase
(AMPK), a key player in insulin-independent signaling
(for a review see [33]). However, no significant differ-
ences between wt and mutant mice were found (data
not shown).
Normal expression levels but compromised translocation
of GLUT4 in mdx muscle
As the major insulin-dependent glucose transporter in
muscle and adipose tissues, GLUT4 is largely responsibles were determined in plasma (A) (n = 6 per genotype; ***P < 0.001)
mRNA levels in QF muscle lysates were determined by qPCR relative
= 4 per genotype; *P < 0.05). (D) EBD penetration into EDL muscle
m dye-injected mice (n = 3 per genotype, whole cross-sectional areas
s in mdx mice. Data in A-C are presented as mean ± SEM.
Figure 3 (See legend on next page.)
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Figure 3 Analysis of glucose metabolism and visualization of GLUT4 translocation. (A) Blood glucose levels of wt and mutant mice were
assessed by oGTT (n ≥ 5 per genotype). Note elevated glucose levels in mdx mice, 30, 45, and 60 minutes after force-feeding of glucose
(**P < 0.01). (B) Insulin levels were measured in blood during oGTT (n ≥ 5 per genotype, differences are not statistically significant). (C) Bar graph,
representative immunoblot, and corresponding Coomassie-stained gel, showing GLUT4 protein levels in mutant relative to wt (100%) GC muscles
(n = 4 per genotype). Differences are not statistically significant. Positions of molecular mass markers are indicated. (D) Immunolocalization and
quantification of GLUT4 on cryosections of QF muscles from wt and mutant mice. Note increased immunoreactivity of GLUT4 at the periphery of
myofibers in wt, cKO and dKO compared to mdx mice (***P < 0.001); details of quantification are described in the text. (E) Fluorescence
microscopy of GFP-P1f-overexpressing (P1f-transfected) and control (Ctrl; GFP-P1f-untransfected) differentiated myotubes, both expressing a
mCherry-HA-GLUT4 fusion protein; a topographic scheme of the mCherry-HA-GLUT4 fusion protein is shown below micrographs. Note reduced
labeling of HA (yellow) in P1f-transfected compared to control myotubes. Bar, 10 μm. (F) Quantification of GLUT4 translocation. GLUT4 (mCherry)
signals colocalizing with extracellular HA-tag signals were measured as described in the text. Note, surface GLUT4 labeling was reduced to 54% in
differentiated myotubes overexpressing GFP-tagged P1f (P1f) compared to control cells (Ctrl) (n ≥ 13 per genotype; four independent
experiments, ***P < 0.001). Bar, 10 μm. Data in (A-D), and F represent mean ± SEM.
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tion. To examine whether the observed metabolic pheno-
type of mdx mice and its rescue in dKO mice were
reflected in altered expression levels or intracellular
localization of GLUT4, we quantitated total GLUT4 pro-
tein levels in muscle lysates by immunoblotting and
measured the relative intensities of GLUT4-specific im-
munostaining in peripheral (sarcolemmal) and interior
(cytoplasmic) subcompartments of cryosectioned QF
muscle fibers. While immunoblots showed that the levels
of GLUT4 were similar in all genotypes (Figure 3C), quan-
titative analysis of immunofluorescent images clearly re-
vealed a higher concentration of GLUT4 in peripheral
versus interior regions in wt, cKO, and dKO fibers, but
not in those from mdx muscle (Figure 3D).
To establish a direct link between sarcolemmal-
associated plectin and GLUT4 translocation, we devel-
oped an assay where GLUT4 translocation could be
monitored ex vivo. For this, we mimicked the plectin-
specific situation in mdx muscle fibers by overexpressing
a GFP-tagged variant of the sarcolemma-associated
plectin isoform P1f in a myoblast cell line [11] that ex-
presses dystrophin at normal levels. To monitor GLUT4
and visualize translocated molecules at the same time,
cells were cotransfected with an expression plasmid en-
coding mCherry-GLUT4 with an additional antibody-
detectable HA-tag in its extracellular domain. After
transfection, cells were subjected to differentiation for
seven days and were then incubated with insulin to
stimulate GLUT4 translocation. Scoring myofibers for
membrane-recruited GLUT4 (co-localization of HA-tag
and mCherry signals) in GFP-negative (control) and
GFP-positive (P1f-overexpressing) myofibers (Figure 3E),
we found GLUT4 translocation to the plasma membrane
to be reduced by 46% (P < 0.001) in myofibers over-
expressing P1f (Figure 3F). A number of control experi-
ments supported the validity of these results. First, when
myoblasts were transfected with a plasmid (mCherry-HA)
encoding a fusion protein of mCherry and the HA-tagwithout the GLUT4 sequence, no extracellular HA immu-
noreactivity was detectable, whereas after fixation and
permeabilization of cells, the HA-tag was clearly visualized
(Additional file 5: Figure S4). Second, the protein levels of
overexpressed P1f in cultured myotubes (estimated by
quantitative immunofluorescence microscopy) were twice
as high (approximately 200%) as those in non-transfected
cells; thus they were in the range of the P1f levels esti-
mated for mdx myofibers (approximately 170% total
plectin, and approximately 150% P1f in membrane prepa-
rations; see [7], and data not shown). Third, testing the
maturity of the myofibers used in the translocation assay,
immunofluorescence microscopy revealed a pronounced
striated staining pattern of sarcomeric α-actinin, typical of
mature myofibers (Additional file 6: Figure S5). Together,
the reduced GLUT4 translocation upon overexpression of
P1f observed ex vivo and the decreased levels of
sarcolemma-associated GLUT4 seen in vivo, provided
strong evidence for sarcolemma-associated plectin directly
affecting GLUT4-trafficking, albeit the underlying mech-
anism remained obscure.Plectin destabilizes subsarcolemmal MT networks
GLUT4 translocation occurs in the cytoplasm via storage
vesicles that are transported along MTs to the cell periph-
ery upon activation of the insulin receptor signaling path-
way [34,35]. We reasoned that the compromised GLUT4
translocation observed in myocytes overexpressing P1f
might be due to MT network alterations effected by
plectin. To assess this idea, we first visualized MT net-
works of myofibers cotransfected with GFP-P1f and
mCherry-GLUT4 by immunofluorescence microscopy
using anti-α-tubulin antibodies and compared them with
those of myofibers transfected with mCherry-GLUT4
alone (no GFP-P1f). As best seen in juxtaposed transfected
and non-transfected cells (Figure 4A) and confirmed by
quantitative analysis (Figure 4B), the MT network density
was substantially reduced in P1f-overexpressing fibers
Figure 4 (See legend on next page.)
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Figure 4 Comparative phenotypic analyses of MT networks in wt and mutant muscles. (A) Fluorescence microscopy imaging of P1f,
GLUT4, and tubulin in GFP-P1f/mCherry-GLUT4-double transfected myocyte cultures after seven days of in vitro differentiation. Of the two
adjacent cells shown in the center, one is double-transfected, overexpressing full-length P1f (green) and GLUT4 (red), while the other is single
transfected, expressing only GLUT4. Note reduced density of MT network (amber) in the P1f-expressing cell (especially in regions with high P1f
expression) due to lower number of MTs. Blue, nuclei. Bar, 10 μm. (B) Quantification of MTs in differentiated myocytes with or without
overexpressed P1f. Note reduction of MT-specific signal in myotubes expressing GFP-tagged P1f (P1f) to 62.7% relative to control cells (Ctrl, 100%)
(n ≥ 12 per genotype; four different myotubes per genotype; ***P < 0.001). (C) Teased EDL muscle fibers (from wt and mutant mice) were
immunolabeled using primary antibodies to α-tubulin. Arrowheads, positions of virtual cross-sections shown in small panels. Bars, 10 μm. Blue,
nuclei. (D and E) Quantitative immunoblotting analysis of GC muscle lysates using antibodies to α-tubulin (D) (n = 4 per genotype, **P < 0.01
compared to wt), or antibodies to acetylated tubulin (E) (n = 4 per genotype), with corresponding Coomassie-stained gels. Values represent
percentages relative to wt (100%); are shown. Note that in (E) no significant differences were observed between any of the samples. (F) Total
length of MTs (per cell area) measured after nocodazole treatment of primary myofibers. MTs were visualized as in (C); (n ≥ 65 per genotype;
*P < 0.05, **P < 0.01). Representative examples of cells subjected to the measurements are shown in Additional file 7: Figure S6. (G) Quantitative
immunoblotting analysis of GC muscle lysates using antibodies to tau with corresponding Coomassie-stained gel. Note elevated levels of high
molecular weight (HMW) isoforms of tau in dKO and cKO muscles compared to wt (100%) and mdx (109%) specimens (n = 4 per genotype;
*P < 0.05, **P < 0.01). Positions of molecular mass marker (kDa) are indicated in immunoblots and corresponding Coomassie-stained gels
(D, E, and G). Data in bar graphs (D-G) are presented as mean ± SEM.
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MTs were especially scarce in regions with high concentra-
tions of P1f and more prominent in P1f-free regions, such
as around the nuclei.
To visualize subsarcolemmal MT networks in intact
myofibers, we prepared teased myofibers from EDL
muscle of adult mice and subjected them to confocal im-
munofluorescence microscopy (Figure 4C). In specimens
from mdx mice, MT networks were found to be reduced
and disorganized (particularly in subsarcolemmal re-
gions) compared to wt mice. Disorganization of MT net-
works in mdx mice, originally reported by Percival et al.
[36], has recently been attributed to the loss of
dystrophin’s MAP-like MT-stabilizing function [37]. In
sharp contrast, in cKO and more so in dKO mice, MT
networks were more prominent, appearing more robust
compared to wt mice. Especially in fibers from dKO
mice, thick, longitudinal bundles located underneath the
sarcolemma were strikingly visible (Figure 4C). The differ-
ences in sarcolemma-associated MTs became particularly
evident in virtual cross sections, where prominent
tubulin-positive patches were clearly visible at the sarco-
lemma of wt, cKO, and dKO fibers, but were rarely seen
in mdx fibers (Figure 4C, right panels). These data sug-
gested that sarcolemma-associated dystrophin and plectin
were influencing MT network formation at the plasma
membrane in antagonistic ways. As MT networks in fibers
without plectin (dKO and cKO) were more prominent
than in wt fibers, while the opposite was true for mdx fi-
bers (where plectin was overexpressed), plectin, contrary
to dystrophin, seemed to destabilize MTs.
Tubulin incorporated into stably assembled MTs be-
comes acetylated by an acetyltransferase while disassembled
tubulin as well as highly dynamic MTs remain unacetylated.
This post-translational modification thus serves as a marker
of MTs endowed with a long half-life. To gain insight into
the dynamic state of MTs in myofibers of mdx versus cKOand dKO mice, we determined the protein expression levels
of α-tubulin and the proportion of acetylated tubulin. Un-
expectedly, we found that the levels of total (soluble and in-
soluble) α-tubulin were extensively (four to eight-fold)
increased in muscles from mice with muscular dystrophy
compared to wt littermates (Figure 4D). However, the amount
of acetylated tubulin was not, or only insignificantly increased
in cKO, mdx, and dKO muscles (Figure 4E), indicating that
the bulk of tubulin found in these samples was unacetylated.
To assess and compare MT stability in mutant myocytes
in a more direct way, we isolated primary myoblasts from
cKO, mdx, and dKO littermates, let them differentiate to
myotubes, and exposed these to low doses of the MT-
depolymerizing drug nocodazole. By determining the total
lengths of drug-resistant MTs per cell area by immuno-
fluorescence microscopy, we found that MT polymers
were clearly more abundant in cKO and dKO compared
to mdx myotubes (Figure 4F, representative examples of
measured cells are given in Additional file 7: Figure S6).
This indicated that MTs in mdx myotubes were less stable
than those in plectin-deficient cells. As the stability of
MTs is regulated by MAPs, we determined the expression
levels of tau, one of the main MAPs expressed in muscle
tissue [38]. When cell lysates prepared from whole mus-
cles were compared by immunoblotting, the levels of tau
found in the cKO and dKO samples were significantly
higher than in the mdx samples (Figure 4G) consistent
with the data shown in Figures 4C and F. Similar observa-
tions were made for MAP4, another MAP expressed in
muscle (data not shown). Based on these data it appears
that sarcolemma-associated dystrophin and plectin have
antagonistic impacts on the dynamics of subplasma mem-
brane MT networks. While dystrophin stabilizes these net-
works, plectin destabilizes them. This mechanism would
explain why the elimination of plectin from mdx muscle
fibers rescues their capacity to recruit MTs to the mem-
brane, thereby restoring GLUT4 translocation.
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Having shown previously that P1f is overexpressed at
the sarcolemma of mdx mice [7], in this study we asked
the question whether plectin overexpression was con-
tributing to the mdx muscle tissue necrosis phenotype,
or whether it had an ameliorating effect. By comparing
the histopathology of plectin/dystrophin dKO, mdx, and
plectin cKO mice, it became clear that, overall, the add-
itional lack of plectin in dKO mice was aggravating the
muscular dystrophy phenotype of mdx mice, not at least
because of the early death of double-deficient mice. The
overexpression of plectin in mdx muscle could be seen
as a cellular response to dystrophin deficiency that coun-
teracts the compensatory action of upregulated utrophin
under these conditions [39]. While our study demon-
strates that plectin’s accumulation at the sarcolemma of
regenerating mdx muscle fibers does not relieve their
structural deficits but rather adds an additional deficit
that affects the metabolism of the fiber by inhibiting its
glucose uptake, pharmacologically-induced further
upregulation of utrophin was shown to ameliorate the
dystrophic phenotype of mdx muscle [40]. Our study
further suggests that the reduced glucose metabolism
of mdx mice is due to excessive subsarcolemmal
plectin acting as a local antagonist of MT network for-
mation in peripheral areas of myofibers with severe
consequences for MT-dependent functions.
The molecular mechanism underlying MT destabiliza-
tion through excess plectin in myofibers has yet to be
unraveled. It is possible that plectin affects MTs either
directly by inhibiting tubulin assembly into polymers, or
indirectly by acting as a deregulator of MT assembly-
promoting MAPs. We consider deregulation of MAPs as
the more likely mechanism in light of plectin’s known
interaction with various MAPs [41,42], including the tau
isoforms shown to be expressed in skeletal muscle
(Figure 4G). Moreover, a similar destabilizing effect of
plectin on MTs could recently be demonstrated in
keratinocytes [42].
As proposed in the model presented in Figure 5,
incorporation of GLUT4 into the membrane is reduced
in P1f-overexpressing mdx myofibers (consistent
with their defective glucose uptake), whereas under
normal conditions (wild-type), or in situations where
no plectin is encountered at the membrane (cKO,
dKO; and where glucose uptake is normal), insulin-
stimulated GLUT4 transport towards the membrane
can take place along MTs in an undisturbed way. We ex-
pect that plectin affects also other types of MT-dependent
vesicular transport processes, one of which could be the
transport of dysferlin. As a protein involved in the second-
ary (inflammatory) response to injury [43-45], it has been
suggested that dysferlin is translocated along MTs due to
its in vitro interaction with α-tubulin and partialcolocalization with polymerized MTs [46]. In this context
it is of interest that dysferlin expression levels in GC
muscle cell lysates from dKO mice were found to be two-
to three-fold increased, compared to cKO and mdx
mice, and approximately 10-fold relative to wt (unpub-
lished data). Whether the upregulation of dysferlin and
increased MT network stability observed in dKO muscle
lead to a more efficient transport of the protein to the
sarcolemma and eventually to improved sarcolemma
repair, remain interesting questions to be investigated.
Nishimura and colleagues suggested that MTs play an
important role in cellular biomechanics [47]. They showed
that cardiomyocytes with hyperpolymerized MTs (pacli-
taxel-treated) exhibit increased shear stiffness compared
to untreated cardiomyocytes, whereas in cells with
depolymerized MTs (colchicine-treated) a decrease in lon-
gitudinal shear stiffness was observed. Visualization of
MTs in paclitaxel-treated cardiomyocytes revealed espe-
cially the longitudinal MTs to be increased, similar to
our observation in skeletal muscle of dKO mice.
Therefore, we speculate that mechanical load of dKO
myofibers (stiffened through the accumulation of MTs
underneath the sarcolemma) could make them more
susceptible to bursting (at least relative to wt and
cKO myofibers), leading to necrosis that manifests as
elevations of CK plasma levels and of neutrophile
granulocytes. Increased stiffness would also explain
why dKO mice show a more severe structural pheno-
type compared to cKO and mdx mice.
Interestingly, despite exhibiting a reduced number of
glycolytic type II fibers, dKO mice do not show dimin-
ished glucose uptake. This could be due to MTs lying
directly underneath the sarcolemma, thereby positioning
GLUT4 vesicles close enough to the membrane to allow
glucose uptake even without insulin-triggering. Thus,
also at times of low or no food consumption, myofibers
are probably competing for glucose and in case of crit-
ical shortage, the muscle is switching to oxidative phos-
phorylation and finally to muscle wasting, leading to
smaller fiber diameters, reduced weight, and early death
of dKO mice.
Implying an involvement of plectin 1f in metabolic
processes, our study adds another important aspect
to the functional repertoire of this highly versatile
cytolinker protein. Isoform 1f has previously been
shown to play a crucial role in muscle maintenance by
linking the desmin network to the dystroglycan protein
complex [7]. Moreover, it has recently been found that
patients bearing mutations in the exon encoding its
isoform-specific N-terminal sequence are suffering
from limb-girdle muscular dystrophy (mostly affect-
ing shoulder and hip muscles) but not from skin blis-










Figure 5 Schematic model of GLUT4 and MT distribution in wt, mdx, cKO, and dKO myofibers. Plasma membrane resident GLUT4 and
juxtamembrane-positioned MTs are depicted as being reduced in (P1f-overexpressing) mdx myofibers compared to the other genotypes; whereas
in cKO and dKO myofibers subsarcolemmal MT network densities are increased. The model makes differences in MT network density and
membrane anchorage accountable for how efficiently GLUT4-containing vesicles are transported towards the sarcolemma, with a low point in
the case of mdx muscle.
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genetic and pharmacological therapies for DMD, lead-
ing to a deceleration of disease progression. However, a
cure for the disease has not become available so far.
Previous and present studies have/are focused on either
the re-expression of ‘mini-dystrophin’, a shorter version
of the protein [49]; or skipping the mutated exon using
antisense oligonucleotides [50]; or pharmacologically
enabling the ribosome to read through the premature
stop codon of the mutated dystrophin gene [51]. None
of these approaches led to more than 15% re-expression
of dystrophin [52]. This low level of restoration is prob-
ably insufficient to overcome the potentially damaging
effects, such as deregulation of MT-dependent pro-
cesses and signal transduction events, caused by
plectin’s accumulation at the sarcolemma as seen in
DMD patients and mdx mice. Thus, for a more efficient
rescue of muscular dystrophy in patients, therapeuticstrategies aiming at a balanced expression of sarcolemmal
levels of both, dystrophin and plectin, could prove useful.
Conclusions
In conclusion, the comparative phenotypic analyses of
mouse lines lacking either dystrophin (mdx), or plectin
(MCK-Cre/cKO), and of a newly generated double KO
mouse line lacking both proteins, revealed that the impair-
ment of glucose uptake observed in mdx mice is due to
the overexpression of plectin at the sarcolemma of their
myofibers. Our results suggest that plectin, upon accumu-
lation at the sarcolemma of mdx myofibers, acts as an an-
tagonist of MT network formation thereby impeding
MT-dependent delivery of glucose transporter 4 to the
membrane. This study adds a novel facet to plectin’s
already vast repertoire of functions in cytoskeleton
organization and dynamics and it opens an interesting
new perspective on mechanisms linking the metabolism of
Raith et al. Skeletal Muscle 2013, 3:14 Page 13 of 14
http://www.skeletalmusclejournal.com/content/3/1/14skeletal muscle fibers to their extra-sarcomeric cytoarchi-
tecture. Our study thus provides not only important new
insights into pathomechanisms of plectinopathies but also
muscular dystrophies in general.Additional files
Additional file 1: Figure S1. Immunoblotting and corresponding
Coomassie-stained gel of GC muscle lysates using antibodies to plectin
and dystrophin. Note absence of signals for plectin in cKO, for dystrophin
in mdx, and for both proteins in dKO samples. Positions of molecular
mass markers (kDa) are indicated in immunoblots and corresponding
Coomassie-stained gel.
Additional file 2: Table S1. Summary of phenotypes observed in cKO,
mdx, and dKO in comparison to wt mice (all values represent mean ± SEM).
Additional file 3: Figure S2. Histopathology of soleus and EDL
muscles. Haematoxylin & eosin (H&E), cytochrome-c oxidase (COX),
succinyl dehydrogenase (SDH), nicotinamide adenine dinucleotide
(NADH), periodic acid-Schiff reaction (PAS), trichrome Gomori (TG), and
adenosine triphosphatase (ATPase; pH 4.2) stainings of cryosections from
10-week-old wt and mutant mice are shown.
Additional file 4: Figure S3. White blood cell count. Bar graph shows
white blood cell counts of May-Gruenwald-Giemsa stained blood smears
from wt and mutant mice. Note increased number of granulocytes and
relative reduction of lymphocytes (characteristics of severe tissue
necrosis) in dKO mice (*P < 0.05; n = 5 per genotype; data presented as
mean ± SEM).
Additional file 5: Figure S4. Control experiment for GLUT4
translocation assays (see Figures 1D and E) using pmCherry-HA (without
GLUT4-encoding sequence) instead of pmCherry-HA-GLUT4 for
transfection. Note that the expressed mCherry-HA fusion protein is not
immunodetectable (not surface-exposed) under nonpermeabilizing
conditions, but only after permeabilization of cells. Bar, 10 μm.
Additional file 6: Figure S5. Immunofluorescence microscopy of
sarcomeric α-actinin in myoblasts used for the quantification of GLUT4
translocation (differentiated for seven days). Note pronounced striated
staining pattern, a characteristic feature of mature myofibers.
Additional file 7: Figure S6. Micrographs showing representative
immunofluorescence images used for MT length assessment (total length
of MTs per cell area) in nocodazole-treated primary myofibers.
Arrowheads indicate the beginning and end of one of at least 65 MTs
measured in each case. Note generally reduced lengths of MTs in mdx
specimens. Bar, 10 μm.Abbreviations
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